VRDN Stock Price, Viridian Therapeutics, . Quote, Chart

Market Summary

USD12.70-0.33

Market Closed

-2.53%

VRDN Stock Price

View Fullscreen

VRDN RSI Chart

VRDN Valuation

Market Cap

797.1M

Price/Earnings (Trailing)

-3.35

Price/Sales (Trailing)

59.51

Price/Free Cashflow

-4.31

VRDN Price/Sales (Trailing)

VRDN Profitability

Operating Margin

86.27%

Return on Equity

-53.78%

Return on Assets

-48.48%

Free Cashflow Yield

-23.22%

VRDN Fundamentals

VRDN Revenue

Revenue (TTM)

18.6M

Rev. Growth (Yr)

298.85%

Rev. Growth (Qtr)

-3.73%

VRDN Earnings

Earnings (TTM)

-237.7M

Earnings Growth (Yr)

-46.03%

Earnings Growth (Qtr)

-40.29%

Breaking Down VRDN Revenue

Last 7 days

-16.2%

Last 30 days

-26.9%

Last 90 days

-36.1%

Trailing 12 Months

-54.0%

How does VRDN drawdown profile look like?

VRDN Financial Health

Current Ratio

18.26

Debt/Equity

0.05

Debt/Cashflow

-9.12

VRDN Investor Care

Shares Dilution (1Y)

30.65%

Diluted EPS (TTM)

-5.31

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	6.1M	0	0	0
2022	1.7M	874.0K	1.7M	1.8M
2021	1.7M	2.6M	2.8M	3.0M
2020	4.9M	2.6M	1.9M	1.1M
2019	4.0M	4.3M	4.1M	4.5M
2018	8.3M	9.8M	9.1M	8.4M
2017	3.0M	2.6M	3.3M	4.0M
2016	2.8M	3.2M	3.6M	3.5M
2015	3.9M	3.4M	3.0M	2.5M
2014	4.3M	4.8M	5.7M	4.3M
2013	0	4.4M	4.3M	4.3M
2012	0	0	0	4.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Viridian Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	fairmount funds management llc	sold	-	-	-5,859	-
Mar 28, 2024	fairmount funds management llc	acquired	-	-	5,859	-
Jan 22, 2024	fairmount funds management llc	bought	9,999,990	21.00	476,190	-
Jun 16, 2023	meisner lara	acquired	621	23.03	27.00	chief legal officer
Jun 16, 2023	meisner lara	sold	-765	28.35	-27.00	chief legal officer
Jun 15, 2023	meisner lara	sold	-63,577	28.02	-2,269	chief legal officer
Jun 15, 2023	meisner lara	acquired	52,255	23.03	2,269	chief legal officer
Jun 06, 2023	meisner lara	acquired	94,882	18.51	5,126	chief legal officer
Jun 06, 2023	meisner lara	sold	-128,253	25.02	-5,126	chief legal officer
Jun 05, 2023	meisner lara	sold	-12,490	25.03	-499	chief legal officer

Which funds bought or sold VRDN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	AlphaCentric Advisors LLC	new	-	105,060	105,060	0.06%
Apr 24, 2024	Carmichael Hill & Associates, Inc.	unchanged	-	-171	701	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-68.85	-88,000	30,000	-%
Apr 22, 2024	StoneCrest Wealth Management, Inc.	reduced	-0.42	-120,699	484,589	0.42%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	12.92	-20,543	202,223	-%
Apr 22, 2024	Vivo Capital, LLC	unchanged	-	-7,165,940	29,385,400	2.31%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	143,425	485,062	-%
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	added	44.92	272,460	1,922,950	0.10%
Apr 16, 2024	VOISARD ASSET MANAGEMENT GROUP, INC.	unchanged	-	-427	1,751	-%
Apr 12, 2024	Game Plan Financial Advisors, LLC	unchanged	-	-55.00	228	-%

Are Funds Buying or Selling VRDN?

Are funds buying VRDN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VRDN

No. of Funds

Unveiling Viridian Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 01, 2024	fairmount funds management llc	18.64%	13,956,685	SC 13D/A
Feb 14, 2024	commodore capital lp	3.7%	1,924,074	SC 13G/A
Feb 14, 2024	deep track capital, lp	9.90%	5,378,997	SC 13G/A
Feb 14, 2024	venrock healthcare capital partners iii, l.p.	9.99%	5,555,568	SC 13G/A
Feb 14, 2024	paradigm biocapital advisors lp	9.99%	5,304,313	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	-	0	SC 13G/A
Feb 13, 2024	vanguard group inc	5.71%	3,000,948	SC 13G/A
Jan 29, 2024	blackrock inc.	6.5%	3,426,450	SC 13G/A
Jan 29, 2024	perceptive advisors llc	6.7%	4,022,066	SC 13G
Jan 24, 2024	state street corp	5.15%	2,708,383	SC 13G

Recent SEC filings of Viridian Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	8-K	Current Report
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	SC 13D/A	13D - Major Acquisition
Feb 28, 2024	S-8	Employee Benefits Plan
Feb 27, 2024	10-K	Annual Report
Feb 27, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	3	Insider Trading
Feb 14, 2024	4	Insider Trading
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Viridian Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.15%	-18.78%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.46%	-27.26%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	-6.36%	-11.66%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.50%	-30.40%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.92	14.56	425.83%	18.94%
BBIO	4.3B	-	-18.25%	70.26%	-6.55	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.16	12.52	440.80%	-27.84%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.12	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-8.32%	-19.69%	-43.85	3.7	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.79%	-8.36%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-16.14%	-47.54%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-7.41%	335.24%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.26%	4.12%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

Viridian Therapeutics, Inc. News

Latest updates

Viridian Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-100.0%	-	4,164	4,326	4,487	291	1,044	256	196	214	208	1,090	1,451	54.00	-	168	828	880	695	2,514	372	476
Operating Expenses	39.5%	71,550	51,296	59,347	72,571	49,171	30,980	29,820	26,105	29,295	14,342	19,088	19,966	90,652	5,410	6,542	8,826	10,951	11,925	11,456	12,108	10,929
S&GA Expenses	57.8%	32,993	20,911	19,264	21,831	9,854	8,861	8,108	8,359	6,901	6,221	6,523	6,160	5,537	2,299	2,706	2,723	2,534	2,898	2,857	3,357	2,695
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,111	3,836	6,103	8,417	9,027	8,599	8,751	8,234
Interest Expenses	-	452	-	-	-	149	77.00	-	-	-	-	-	-	69.00	53.00	84.00	61.00	105	129	141	136	131
Net Income	-40.3%	-66,860	-47,660	-55,063	-68,151	-45,785	-28,905	-29,491	-25,693	-28,946	-14,043	-17,964	-18,460	-90,742	-5,494	-6,435	-8,044	-10,118	-11,230	-8,896	-11,629	-10,317
Net Income Margin	8.7%	-12.81*	-14.02*	-16.04*	-18.69*	-26.34*	-29.92*	-37.41*	-58.90*	-249.73*	-50.38*	-51.12*	-72.40*	-105.44*	-	-	-	-	-	-	-	-
Free Cashflow	3.4%	-38,048	-39,387	-45,545	-62,088	-34,273	-20,763	-18,378	-21,221	-16,619	-12,061	-14,685	-11,554	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	49.2%	490	329	351	387	435	441	170	183	204	221	118	123	131	33.00	33.00	39.00	30.00	39.00	49.00	55.00	66.00
Current Assets	50.2%	486	324	346	383	431	437	166	179	200	218	115	122	130	32.00	33.00	38.00	30.00	38.00	48.00	54.00	65.00
Cash Equivalents	-7.9%	103	112	87.00	89.00	156	344	31.00	31.00	42.00	139	28.00	46.00	46.00	30.00	31.00	36.00	25.00	25.00	24.00	18.00	33.00
Net PPE	-7.1%	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00
Liabilities	7.1%	48.00	45.00	36.00	36.00	40.00	32.00	28.00	17.00	16.00	17.00	19.00	17.00	11.00	12.00	12.00	12.00	15.00	16.00	15.00	14.00	15.00
Current Liabilities	14.6%	27.00	23.00	29.00	30.00	33.00	25.00	21.00	14.00	14.00	14.00	17.00	16.00	11.00	8.00	7.00	9.00	10.00	10.00	9.00	7.00	7.00
Long Term Debt	1.0%	20.00	20.00	5.00	5.00	5.00	5.00	5.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	55.9%	442	284	316	351	395	409	142	167	188	205	99.00	106	120	21.00	21.00	27.00	16.00	23.00	33.00	41.00	51.00
Retained Earnings	-10.1%	-725	-659	-611	-556	-488	-442	-413	-384	-358	-329	-315	-297	-278	-188	-182	-176	-168	-158	-146	-137	-126
Additional Paid-In Capital	19.0%	961	807	792	772	741	710	453	439	412	372	260	242	218	209	203	203	184	181	180	179	177
Shares Outstanding	23.5%	54.00	44.00	44.00	43.00	41.00	29.00	28.00	26.00	12.00	8.00	8.00	6.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	1,021	-	-	-	329	-	-	-	157	-	-	-	59.00	-	-	-	57.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	2.5%	-38,000	-38,983	-45,214	-61,973	-34,042	-20,668	-18,086	-21,042	-16,535	-11,876	-14,631	-11,539	-9,436	-5,095	-6,789	-8,459	-7,806	-9,267	-7,174	-11,809	-8,175
Share Based Compensation	91.4%	26,048	13,606	12,302	15,216	5,278	4,943	4,885	4,659	3,491	3,982	3,817	3,175	1,743	615	623	664	1,003	874	1,075	1,018	937
Cashflow From Investing	-453.3%	-169,711	48,041	40,713	-13,295	-180,603	42,651	13,963	8,863	-80,210	6,251	-11,205	10,872	-52,429	-53.00	-	2,001	7,000	11,021	13,025	-2,820	9,091
Cashflow From Financing	1187.1%	198,941	15,457	3,068	8,204	26,014	290,934	4,558	738	170	116,794	7,052	1,259	77,683	4,645	1,268	17,715	795	-904	-39.00	218	-10.00

VRDN Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Collaboration revenue - related party	$ 314	$ 1,772	$ 2,963
Operating expenses:
Research and development (including related party expenses of $12,035, $5,619, and $— during the years ended December 31, 2023, 2022, and 2021 respectively)	159,765	100,894	56,886
General and administrative	94,999	35,182	25,805
Total operating expenses	254,764	136,076	82,691
Loss from operations	(254,450)	(134,304)	(79,728)
Other income (expense):
Interest and other income	18,563	4,916	318
Interest and other expense	(1,847)	(486)	(3)
Other income, net	16,716	4,430	315
Net loss	$ (237,734)	$ (129,874)	$ (79,413)
Net loss per share, basic (in dollars per share)	$ (5.31)	$ (4.05)	$ (6.66)
Net loss per share, diluted (in dollars per share)	$ (5.31)	$ (4.05)	$ (6.66)
Weighted-average shares used to compute basic net loss per share (in shares)	44,755,475	32,087,293	11,918,712
Weighted-average shares used to compute diluted net loss per share (in shares)	44,755,475	32,087,293	11,918,712
Net loss	$ (237,734)	$ (129,874)	$ (79,413)
Other comprehensive (loss) income:
Change in unrealized (loss) gain on investments	728	(233)	(149)
Total other comprehensive (loss) gain	728	(233)	(149)
Total comprehensive loss	$ (237,006)	$ (130,107)	$ (79,562)

VRDN Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 102,827	$ 155,579
Short-term investments	374,543	268,971
Prepaid expenses and other current assets	9,006	6,521
Unbilled revenue - related party	102	102
Total current assets	486,478	431,173
Property and equipment, net	1,672	1,326
Operating lease right-of-use asset	1,670	1,610
Other assets	604	982
Total assets	490,424	435,091
Current liabilities:
Accounts payable	2,239	14,234
Accrued liabilities and other (including related party of $374 and $1,146 as of December 31, 2023 and 2022, respectively)	24,108	18,827
Current portion of deferred revenue - related party	288	288
Total current liabilities	26,635	33,349
Long-term debt, net	20,205	4,645
Deferred revenue - related party	573	861
Other liabilities	989	1,172
Total liabilities	48,402	40,027
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.01 par value; 200,000,000 shares authorized; 53,986,112 and 41,305,947 shares issued and outstanding as of December 31, 2023 and 2022, respectively	540	414
Additional paid-in capital	960,536	741,067
Accumulated other comprehensive gain (loss)	338	(390)
Accumulated deficit	(725,908)	(488,174)
Total stockholders’ equity	442,022	395,064
Total liabilities and stockholders’ equity	490,424	435,091
Series A Preferred Stock
Stockholders’ equity:
Preferred stock	78,235	85,470
Series B Preferred Stock
Stockholders’ equity:
Preferred stock	$ 128,281	$ 56,677

About Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004, a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006, a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts.

CEO	Mr. Scott D. Myers M.B.A.
WEBSITE	viridiantherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	86

Viridian Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Viridian Therapeutics, Inc.? What does VRDN stand for in stocks?

VRDN is the stock ticker symbol of Viridian Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Viridian Therapeutics, Inc. (VRDN)?

As of Thu Apr 25 2024, market cap of Viridian Therapeutics, Inc. is 797.15 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VRDN stock?

You can check VRDN's fair value in chart for subscribers.

What is the fair value of VRDN stock?

You can check VRDN's fair value in chart for subscribers. The fair value of Viridian Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Viridian Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VRDN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Viridian Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether VRDN is over valued or under valued. Whether Viridian Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Viridian Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VRDN.

What is Viridian Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, VRDN's PE ratio (Price to Earnings) is -3.35 and Price to Sales (PS) ratio is 59.51. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VRDN PE ratio will change depending on the future growth rate expectations of investors.